AxoSim
Building human brains in the lab at scale to heal memory, movement, and pain disorders.
Founded 2014
New Orleans, United States
20 employees
Venture round
Total: $10.05M
Biopharma, Biotechnology +1
New Orleans, United States
20 employees
Venture round
Total: $10.05M
Biopharma, Biotechnology +1
General Information
Company Name
AxoSim
Founded Year
2014
Location
New Orleans, United States
New Orleans, United States
Employees
20
Industries
Biopharma, Biotechnology, Life Sciences
Funding Stage
Venture round
Social
BounceWatch is an independent company data service, not affiliated with AxoSim. To contact AxoSim, visit axosim.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does AxoSim compare?
A PDF of AxoSim and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting AxoSim soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is AxoSim on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biopharma
About AxoSim
Business keywords: Drug Development, Preclinical Testing, Neurotoxicity, Neuroefficacy, 3D Cell Assays, Neurodegenerative Disease Models, Myelination Models, Nerve-on-a-Chip, Organ-on-a-Chip, Peripheral Neuropathy, Toxicology, Neuroscience, Organoids
Funding Rounds & Investors (11)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | $6.06M | - |
|
10 Jun 2021 |
| Series A | Undisclosed | 1 |
|
28 May 2021 |
| Private Equity Round | Undisclosed | 2 |
|
05 Nov 2020 |
| Seed Round | Undisclosed | 1 |
|
01 Jun 2019 |
| Venture Round | $1.13M | 1 |
|
07 Mar 2019 |
| Grant | $200.00K | 1 |
National Institutes of Health
|
21 Sep 2018 |
| Grant | $665.00K | 1 |
National Institutes of Health
|
01 Sep 2018 |
| Grant | $1.77M | 1 |
National Institutes of Health
|
14 Sep 2017 |
| Seed Round | Undisclosed | 1 |
|
03 Aug 2017 |
| Seed Round | Undisclosed | 4 |
|
01 Apr 2017 |
AxoSim Alternatives & Competitors
View All Alternatives
AxoSim vs
CN Bio
United Kingdom
Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems.
Series B
59 employees
Biopharma, Biotechnology
AxoSim vs
AlveoliX
Switzerland
In-vitro models inspired by nature Ι Organs-on-Chip
Grant
11 employees
Biotechnology, Life Sciences
AxoSim vs
Emulate, Inc.
United States
Our Organ-on-a-Chip technology provides a high-fidelity window into the inner workings of human biol...
Series F
71 employees
Biotechnology, Health Care
FAQ About AxoSim
Building human brains in the lab at scale to heal memory, movement, and pain disorders.
AxoSim was founded in 2014.
AxoSim is headquartered in New Orleans, United States.
AxoSim operates in Biopharma, Biotechnology and Life Sciences. Its work centres on Drug Development, Preclinical Testing, Neurotoxicity and Neuroefficacy.
AxoSim has approximately 20 employees.
AxoSim has completed 11 funding rounds, raising a total of $10.05M. The latest funding stage is Venture round.
Top alternatives and competitors to AxoSim include CN Bio, AlveoliX , Emulate, Inc., OrganoTherapeutics, Qureator . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AxoSim and CN Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for AxoSim, https://bouncewatch.com/company/axosim-1, updated 30 December 2024. When citing, please name BounceWatch and link this page.
